Oncotelic Therapeutics (OTCQB: OTLC) said its 45%-owned joint venture, Sapu Nano, reported new data at the 2025 San Antonio Breast Cancer Symposium showing that its Deciparticle(TM) nanomedicine platform can consistently formulate structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams and polyketides—into sub-20 nm nanoparticles suitable for IV delivery. The Company said the findings confirm Deciparticle as a versatile, cGMP-ready delivery platform backed by ISO-5 manufacturing capabilities that support rapid translation to Phase 1 supply. CEO Dr. Vuong Trieu said the results position Deciparticle as a modular engine for multiple oncology, immunology and peptide drug candidates, with Sapu003 representing the first of a broader pipeline.

To view the full press release, visit https://nnw.fm/b0Qps

About Oncotelic Therapeutics Inc.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN